Skip to content
DataLookout
Menu

NCT05017025

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 11 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed Show 4 more changesShow less
    • Primary completion date changed from estimate of Jun 7, 2028 to Sep 15, 2026
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Study description revised
  2. Notable Primary and study completion pushed from Jun 30, 2026 to Jun 7, 2028v20
  3. Notable Primary and study completion dates: Jun 30, 2025 to Jun 30, 2026v16
  4. Study Identification, Study Status, Oversight, Conditionsv13
  5. Study Identification, Study Status, Oversight, Conditionsv12
Show 5 earlier versionsHide 5 earlier versions
  1. Notable Primary and study completion dates: May 25, 2024 to Jun 30, 2025v9
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 30 to confirmed 32
    • Site details revised
    v7
  3. Minor Eligibility criteria shortened, about 35 wordsv5
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 31, 2022 to Feb 17, 2022
    • Site details revised
    v3
  5. Study Status, Referencesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose-limiting toxicity and recommended phase 2 dose
Timeframe: Up to 30 days after last dose

Secondary (3)

Progression-free survival
Best objective response rate
Overall survival

Arms and interventions

Treatment (osimertinib, aurora A kinase inhibitor LY3295668)Experimental

Patients receive osimertinib PO QD and aurora A kinase inhibitor LY3295668 PO BID on days 1-28. Treatment repeats every 28 days for 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.

Drugs: Aurora A Kinase Inhibitor LY3295668, Osimertinib

Sites

1 site in 1 country

  • M D Anderson Cancer CenterHouston, Texas, United States